SU858830A1 - Agent for treating cardiac rythm distortions - Google Patents

Agent for treating cardiac rythm distortions Download PDF

Info

Publication number
SU858830A1
SU858830A1 SU742069505A SU2069505A SU858830A1 SU 858830 A1 SU858830 A1 SU 858830A1 SU 742069505 A SU742069505 A SU 742069505A SU 2069505 A SU2069505 A SU 2069505A SU 858830 A1 SU858830 A1 SU 858830A1
Authority
SU
USSR - Soviet Union
Prior art keywords
potassium
distortions
agent
treating cardiac
medicine
Prior art date
Application number
SU742069505A
Other languages
Russian (ru)
Inventor
Владимир Николаевич Барнацкий
Владимир Лукич Попков
Василий Михайлович Боголюбов
Станислав Ипполитович Харлампович
Вера Алексеевна Кузнецова
Нина Сергеевна Николаенко
Зоя Петровна Несмелова
Лидия Николаевна Соколова
Лев Бениаминович Шагалов
Валентина Александровна Черняева
Надежда Алексеевна Свидзинская
Ольга Тимофеевна Харламова
Original Assignee
Институт медико-биологических проблем
Московский Государственный Ордена Трудового Красного Знамени Медицинский Стоматологический Институт
Горьковский Химико-Фармацевтический Завод
Институт биофизики
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Институт медико-биологических проблем, Московский Государственный Ордена Трудового Красного Знамени Медицинский Стоматологический Институт, Горьковский Химико-Фармацевтический Завод, Институт биофизики filed Critical Институт медико-биологических проблем
Priority to SU742069505A priority Critical patent/SU858830A1/en
Application granted granted Critical
Publication of SU858830A1 publication Critical patent/SU858830A1/en

Links

Description

Изобретение относитс  к препаратам медицинского назначени , в част ности дл  лечени  сердечно-сосудист системы. Известны препараты дл  лечени  нарушений ритма сердца, содержащие ионы кали  в сочетании с а|шонами хлора, аспарагината fO Однако при введении в организм хлорида кали  из организма вымывают с  анионы угольной кислоты,  вл ющиес  одним из основных компонентов щелочного резерва организма. Известно применение кали  гидрокарбоната в качестве аналитического реактива С2. Цель изобретени  - расшир.е1шё ассортимента средств дл  лече1ш  на рушени  ритма сердца. Поставленна  цель достигаетс  тем, что в качестве средств дл  лечени  нарушений ритма сердца примен ют калий гидрокАрбонат. Дл  лечени  нарушений ритма сердца калий гидрокарбонат ввод т внутривенно капельно в виде 0,5-1%-ного раствора на изотоническом растворе хлорида натри  ежедневно в суточной дозе 2-4. Ректально калий гидрокарбонат ввод т в свечах ежедневно 1-2 раза в день при содержании в одной свече 0,7-0,5-0,3 г кали  гидрокарбоната. Комбинированный способ лечени  предусматривает внутривенное введение 2-4 г кали  гидрокарбоната через день и ежедневное ректальное введение свечей. При введении в организм ионов кали  в сочетании с анионами угольной кислоты в клетках понижаетс  концентраци  водорода, снижаетс  ацидос, повьшаетс  валентность буферных анионов и тем самым создаиотс  услови  дл  вхождени  ионов кали  в клетки. Препарат предназначен дл  восста38588304The invention relates to preparations for medical purposes, in particular for the treatment of the cardiovascular system. Preparations for the treatment of cardiac arrhythmias are known that contain potassium ions in combination with chlorine chlorides, asparaginate fO. However, when potassium chloride is introduced into the body, the anions of carbonic acid, which are one of the main components of the body's alkaline reserve, are washed out of the body. The use of potassium bicarbonate as an analytical reagent C2 is known. The purpose of the invention is to expand the range of products for medical treatment in the rhythm of the heart. This goal is achieved by using potassium hydrocarbonate as agents for treating heart rhythm disorders. For the treatment of cardiac arrhythmias, potassium bicarbonate is administered intravenously in the form of a 0.5-1% solution of sodium chloride with an isotonic solution of sodium chloride daily in a daily dose of 2-4. Rectally, potassium bicarbonate is injected in candles daily, 1-2 times a day, when the content in one candle is 0.7-0.5-0.3 g of potassium bicarbonate. The combined treatment method involves intravenous administration of 2-4 g of potassium bicarbonate every other day and daily rectal administration of suppositories. When potassium ions are introduced into the organism in combination with carbonic anions in the cells, the concentration of hydrogen decreases, the acidos decrease, the valence of the buffer anions increases, and thus conditions for the entry of potassium ions into the cells. The drug is intended to restore 38588304

Claims (1)

но 1ени  калиевого де4ицита в ткан х,Формула изобретени but 1 potassium de4i cite in tissues, claims в частности при нарушени х ритмаПрименение кали  гидрокарбоната в in particular in cases of rhythm disturbances. The use of potassium bicarbonate in сердца, протекающих С нарушениемкачестве средства дл  лечени  нарувозбудимрсти миокарда, вызванныхшений ритма сердца.cardiac arrest With impairment of quality to the treatment of myocardial imbalance caused by cardiac rhythm. длительным назначением диуретических Источники информации,long-term appointment of diuretic sources of information средств, препаратов наперст нки иприн тые во внимание при экспертизеmeans, preparations of a felted nose, are imparted into account during the examination интоксикаци ми,1. Машковский М.Д; Лекарственные npenaijaT не имеет-противопоказа-с. 199-201.intoxication, 1. Mashkovsky M.D .; Medicinal npenaijaT has no contraindications. 199-201. .НИИ, не дает аллергических реакций, ю2. Госудапственна  Фармакопе .NII, does not give allergic reactions, u2. State Pharmacopoe устойчив в хранении,СССР.Изд.Х-е,М./Медицина,1968,с.883,stable in storage, USSR.Izd.X-e, M. / Medicine, 1968, p.883, средства, М., Медицина, 1972, ч.П, means, M., Medicine, 1972, h.P,
SU742069505A 1974-10-23 1974-10-23 Agent for treating cardiac rythm distortions SU858830A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SU742069505A SU858830A1 (en) 1974-10-23 1974-10-23 Agent for treating cardiac rythm distortions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SU742069505A SU858830A1 (en) 1974-10-23 1974-10-23 Agent for treating cardiac rythm distortions

Publications (1)

Publication Number Publication Date
SU858830A1 true SU858830A1 (en) 1981-08-30

Family

ID=20599021

Family Applications (1)

Application Number Title Priority Date Filing Date
SU742069505A SU858830A1 (en) 1974-10-23 1974-10-23 Agent for treating cardiac rythm distortions

Country Status (1)

Country Link
SU (1) SU858830A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004403A1 (en) * 1988-10-21 1990-05-03 The Regents Of The University Of California Treatment of hypertension

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004403A1 (en) * 1988-10-21 1990-05-03 The Regents Of The University Of California Treatment of hypertension

Similar Documents

Publication Publication Date Title
Kelly et al. Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities
Iseri et al. Magnesium and potassium therapy in multifocal atrial tachycardia
Tzivoni et al. Treatment of torsade de pointes with magnesium sulfate.
Dowdy et al. Ventricular arrhythmias induced by succinylcholine in digitalized patients: a preliminary report
Meilman et al. Clinical studies on veratrum alkaloids: I. The action of protoveratrine and veratridine in hypertension
Da Silva et al. Verapamil acute self-poisoning
Page et al. Interrelationships between cardiac effects of ouabain, hypocalcemia and hyperkalemia
Citrin et al. Massive digoxin overdose: Observations on hyperkalaemia and plasma digoxin levels
SU858830A1 (en) Agent for treating cardiac rythm distortions
Jick et al. The effect of calcium chelation on cardiac arrhythmias and conduction disturbances
Cleghorn et al. The treatment of Addison's disease by a synthetic adrenal cortical hormone (desoxycorticosterone acetate)
Nathan et al. Fatal ventricular tachycardia in association with propafenone, a new class IC antiarrhythmic agent
Berg et al. Friedreich's ataxia with acute cardiomyopathy
Shiraki et al. Complete atrioventricular block secondary to lithium therapy
US2259492A (en) Therapeutic preparation of bismuth and method of preparing same
Khalsa et al. Effect of Oral Verapamil on Ventricular Irregularity in Long‐Standing Atrial Fibrillation.
Horler et al. Hypertensive crisis due to pargyline and metaraminol
Burrage et al. Maintenance cortisone in severe bronchial asthma
WOLINTZ et al. Stokes-Adams syndrome and atrial arrhythmias as the presenting symptoms of myotonic dystrophy, with response to electrocardioversion
IL36587A (en) Compositions containing pyridine derivatives and their use in a method of modifying cellular surface reactions
SU1435255A1 (en) Method of recovering antithromogenic activity of vessel wall of cardiological patients
Gilbert et al. Failure of corticotropin to prevent acute hemolytic anemia due to sulfapyridine
Gasperetti Conduction abnormalities complicating carbamazepine therapy
SU789109A1 (en) Method of treating children's active rheumatism
Heilig et al. The influence of intravenous injections of quinine on the myocardium